Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant

To see complete record on, please visit this link

Id: 2019-003984-24

Organisation Name: Central Institute of Mental Health

Start Date: 2020-11-17

Completion Date: Ongoing

Brief Summary: To investigate the safety and efficacy of 25 mg psilocybin (p.o.) in comparison to 5 mg psilocybin (low dose/active placebo) and 100 mg

Country: Germany

Total execution time in seconds: 0.051614999771118